Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000935 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
A Phase 3 study of End Stage Renal Disease and Kidney Transplantation, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00000935: Completed Phase 3 study of End Stage Renal Disease and Kidney Transplantation, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000935 is a Phase 3 study of End Stage Renal Disease and Kidney Transplantation that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 100 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000935, a Phase 3 study of End Stage Renal Disease and Kidney Transplantation, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to test the clinical and laboratory observations that suggest IVIG given before and after kidney transplant to patients who are sensitized (highly sensitive) to certain transplant antigens could result in reduced sensitization and reduced rates of kidney rejection. Some ESRD patients are highly sensitive to certain transplant antigens (foreign substances that activate the immune system) and must wait for a long time before a well-matched kidney becomes available. Transplant rejection is more likely among highly sensitized patients than in patients who are not highly sensitized. There is no proven method to improve a highly-sensitized patient's chances of receiving and keeping a transplanted kidney.
Conditions Studied
Interventions
- BIOLOGICAL Intravenous immune globulin (IVIG)
Study Locations (1)
Maryland
- Ann Limberger - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
What the finished NCT00000935 record still lists
NCT00000935 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Intravenous immune globulin (IVIG) is the first listed.
NCT00000935 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00000935 about?
NCT00000935 is a clinical study titled "An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens". This study is designed to test the clinical and laboratory observations that suggest IVIG given before and after kidney transplant to patients who are sensitized (highly sensitive) to certain transplant antigens could result in reduced sensitization and reduced rates of kidney rejection. Some ESRD ...
What is the current status of trial NCT00000935?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. Estimated completion is 2003-06.
What conditions does trial NCT00000935 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Kidney Transplantation.
What interventions are being tested in trial NCT00000935?
The interventions under investigation include: Intravenous immune globulin (IVIG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00000935?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000935 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000935's enrollment target sits among peer trials
100 34th of 86 higher than 50 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
RECRUITING · Phase 3
-
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
RECRUITING · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
COMPLETED · Phase 3
-
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
COMPLETED · Phase 3
-
Prevention of Kidney Transplant Rejection
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning